8-K: Moleculin Biotech Announces Phase 3 Trial for Annamycin in Relapsed/Refractory AML

Moleculin Biotech is advancing Annamycin, in combination with Cytarabine, to a Phase 3 pivotal trial for the treatment of AML patients who are refractory to or relapsed after induction therapy.

Summary

• Moleculin Biotech held a corporate update webcast to discuss its plans to advance Annamycin in combination with Cytarabine (AnnAraC) to a Phase 3 pivotal trial for relapsed or refractory AML.
• Annamycin is a proprietary anthracycline that the company believes is a true disruptor to this class of drugs, potentially safer and more effective than currently approved anthracyclines.
• Clinical trials to date have shown Annamycin has delivered more than double the complete remission rate of any treatment for relapsed or refractory AML.
• In a study of 14 patients in 2nd and 3rd line treatment, the complete remission rate was 50% with a median durability of remission of 7 months.
• 78% of responders in the study tested MRD negative, which is a strong prognostic indicator for long-term positive outcomes.
• 89% of complete remissions came from subjects with cytogenetics and mutations that are generally considered difficult to treat.
• The Phase 3 trial, named MIRACLE, will be an adaptive design comparing two doses of Annamycin (190 mg/m2 and 230 mg/m2) against a placebo, all in combination with HiDAC.
• The primary endpoint of the trial is complete remission at approximately 1 month, which is expected to expedite the path to approval.
• A second trial, MIRACLE 2, will be conducted for 3rd line subjects, randomizing between the optimal dose of Annamycin and placebo, both combined with high dose Ara-C.
• The company expects to begin enrolling in the MIRACLE trial in the first quarter of 2025 and have unblinded interim data for the first 75 patients by mid-2026.

Sentiment

Score: 9

Explanation: The document is highly positive, emphasizing the potential of Annamycin and the de-risked path to approval. The management's confidence and the strong clinical data contribute to a very optimistic outlook.

Positives

• Annamycin has demonstrated a significantly higher complete remission rate compared to existing treatments for relapsed or refractory AML.
• The median durability of remission has increased to 7 months, indicating a potentially longer-lasting benefit.
• A high percentage of responders tested MRD negative, which is a positive prognostic indicator.
• The FDA has agreed to allow higher doses of Annamycin in the US, which is a significant regulatory win.
• The adaptive Phase 3 trial design is expected to expedite the path to approval.
• The company has a clear timeline for the Phase 3 trial, with interim data expected by mid-2026.
• Annamycin has shown efficacy in patients with difficult-to-treat cytogenetics and mutations.
• The company believes Annamycin has potential uses beyond AML, including other cancers.

Negatives

• The Phase 3 trial will include a comparison of two doses of Annamycin, which could introduce uncertainty about the optimal dose.
• The company will need to conduct a second trial (MIRACLE 2) for 3rd line subjects, which will add time and cost to the development program.
• The company is still in the clinical trial phase and has not yet received regulatory approval for Annamycin.
• The company is relying on historical data for the control arm, which may not be directly comparable to the trial results.

Risks

• The Phase 3 trial may not produce the same positive results as previous trials.
• The FDA may not approve Annamycin even if the trial is successful.
• The company may face challenges in recruiting patients for the trial.
• The company may face competition from other companies developing treatments for AML.
• The company may need to raise additional capital to fund the development program.
• The company's valuation is based on the potential of Annamycin, which is still unproven.

Future Outlook

The company anticipates multiple high-value milestones throughout the Phase 3 development, including a recruitment progress report and unblinded interim data, which are expected to stimulate partnering activity and potential exit opportunities. The company believes the disparity in value will not last and the ultimate exit value for Moleculin shareholders may be measured in the billions.

Management Comments

• Moleculin's proprietary anthracycline is what we believe to be a true disruptor to this well-established class of drugs.
• Based on our clinical trials to date, we believe it may be safer and more effective than any currently approved anthracycline, period.
• We believe that the most important immediate commercial opportunity for Annamycin is that it fills an unmet need for more than half of all AML patients.
• The FDA has now agreed to allow AML patients in the US to be treated, for the first time, above the current lifetime maximum allowable anthracycline dose limit.
• We believe this trial design has de-risked our path to approval.
• We are now entering a period where these milestones will very likely stimulate partnering activity that could lead to the kind of valuation and exit opportunities that our shareholders deserve.

Industry Context

This announcement is significant in the context of the AML treatment landscape, where there is a high unmet need for effective therapies for relapsed or refractory patients. The company is positioning Annamycin as a potential breakthrough in anthracycline therapy, which has been a cornerstone of cancer treatment for over 50 years. The company is also aligning with the FDA's Project Optimus initiative, which encourages developers to avoid higher than necessary dosing.

Comparison to Industry Standards

• The historical performance of HiDAC, a standard treatment for AML, is around 17-18% complete remission rate, while Annamycin has shown more than double that rate in previous trials.
• Existing targeted therapies for AML have an average complete remission rate of around 20%, while Annamycin has demonstrated a higher success rate.
• The company compares Annamycin to drugs like Idhifa and Tibsovo, which were sold for $2 billion, suggesting a potential for significant market value.
• The company claims that Annamycin is relevant to 3 times as many AML patients and has demonstrated more than double the performance for those treated compared to existing targeted therapies.

Stakeholder Impact

• Shareholders are expected to benefit from the potential increase in the company's valuation and exit opportunities.
• Patients with relapsed or refractory AML may have a new treatment option with potentially higher efficacy and safety.
• The medical community may have a new tool to combat AML, particularly in difficult-to-treat cases.

Next Steps

• Begin enrolling in the MIRACLE trial in the first quarter of 2025.
• Provide a recruitment progress report after enrolling the first 40 subjects.
• Review unblinded interim data for the first 75 patients with the FDA in mid-2026.
• Apply for Breakthrough Designation in mid-2026.
• Complete enrollment and begin the NDA process by 2028.

Key Dates

Keywords

Annamycin, AML, Acute Myeloid Leukemia, Phase 3 Trial, MIRACLE Trial, Cytarabine, Anthracycline, Relapsed Refractory, MRD Negative, FDA, HiDAC, Oncology, Cancer Treatment